|
|
|
|
|
Celgene patents stem cell technology
New Jersey-based biotech gets legal protection for method of placental-derived stem cell recovery.
NEW YORK (CNNMoney.com) - Celgene Corp., a biotech specializing in stem cell research, patented its methods for recovering stem cells from a human placenta after birth, the company said. Celgene Cellular Therapeutics, a subsidiary of Summit, N.J.-based Celgene (down $0.16 to $40.45, Research), said that the U.S. patent has been issued and it's the first patent the company has obtained for its stem cell technologies. Celgene said that the placental-derived stem cells "appear to be highly versatile and may have the potential to repair and regenerate a broad range of damaged or diseased tissues." The company said it has additional U.S. patents pending. _______________
To read about the two biggest names in Big Biotech, click here. |
|
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer
| Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use. Intraday data is at least 20-minutes delayed. All times are ET. Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data. Fundamental data provided by Morningstar, Inc.. SEC Filings data provided by Edgar Online Inc.. Earnings data provided by FactSet CallStreet, LLC. |
